A life-threatening complication of a common diabetes drug has doctors racing against time. But a new protocol is changing the game. Metformin-associated lactic acidosis (MALA), a rare but dangerous side effect of the widely used diabetes medication metformin, can be deadly. It happens when lactic acid builds up in the body, causing a dangerous shift in blood chemistry. Researchers have developed a new clinical protocol to improve how MALA is identified and treated. Their findings were presented at ASN Kidney Week 2025. This is a game-changer!
The protocol's core principle? Immediate dialysis. As soon as MALA is diagnosed, the protocol calls for starting dialysis without delay. Doctors can choose from three methods: intermittent hemodialysis, continuous kidney replacement therapy, or peritoneal dialysis. The protocol was first implemented at Maharat Nakhonratchasima Hospital (MNRH) in Thailand. Burirum Hospital (BH) served as a control, continuing with standard care.
Over a five-year study, researchers analyzed a total of 347 cases: 70 at MNRH before the protocol, 129 after, and 148 at BH.
The Results: Dramatic Improvements
The results from MNRH were impressive. The 30-day death rate plummeted from 25.7% before the protocol to 13.9% afterward. At BH, where the protocol wasn't used, mortality rates remained virtually unchanged. And this is the part most people miss: The data from MNRH showed a consistent decline in deaths, dropping by 2.08% each quarter during the study. The time it took to get patients from the hospital door to dialysis also decreased, from 870 minutes to 690 minutes. Awareness of MALA among medical staff also saw a dramatic increase, from 38.5% to 89.9% after the protocol was implemented.
Faster Action, Better Awareness, and Improved Outcomes
"A standardized MALA protocol covering diagnosis, access, and treatment shortened door-to-dialysis time, increased awareness, and reduced care variation," said Dr. Watanyu Parapiboon of Maharat Nakhon Ratchasima Hospital. "Fast-track dialysis pathways should be adopted for time-sensitive conditions like MALA. Availability of all dialysis modalities ensures flexibility and enables timely treatment initiation."
What is Metformin?
Metformin is a frontline medication for type 2 diabetes. It helps the body use insulin more effectively, reduces glucose production in the liver, and increases glucose uptake by muscles. It's known for being effective, affordable, and generally safe, with a low risk of causing low blood sugar. Beyond diabetes, research is exploring metformin's potential benefits for weight management, heart health, and even aging.
What is Metformin-Associated Lactic Acidosis (MALA)?
But here's where it gets controversial... MALA is a rare but serious emergency. It occurs when lactic acid builds up in the bloodstream, a consequence of the body's impaired ability to clear it while taking metformin. This can lead to dangerously low blood pH, muscle weakness, rapid breathing, confusion, and, in severe cases, organ failure or death. MALA often affects patients with kidney problems, liver disease, or conditions that limit oxygen delivery. While rare, it demands immediate diagnosis and treatment, often including dialysis, to remove excess acid and prevent life-threatening complications.
The study: "Reducing Mortality in Metformin-Associated Lactic Acidosis (MALA) Through a Fast-Track Clinical Pathway: A Controlled Interrupted Time Series Quality Improvement Study."
What do you think? Do you believe this new protocol should be widely adopted? Share your thoughts in the comments below!
